Navigation Links
QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
Date:8/31/2010

SYDNEY and BEDMINSTER, N.J., Aug. 31 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal.  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain.  Featured speakers who will highlight Dual Opioids at this symposium are internationally recognised pain experts, Drs. Nicholson, Pasternak and Webster.

In addition to the symposium, QRxPharma was invited to present three posters on September 2, from 9:30-10:30 with the results from MoxDuo IR comparative trials:

  • "Morphine Equivalent Doses of Dual Opioid Treatment With Morphine Plus Oxycodone Versus Morphine and Oxycodone Monotherapy for Post-Operative Pain: Safety and Analgesic Profiles"
  • "Treatment of Post-Operative Pain With a Dual Opioid Combination of Morphine and Oxycodone: Analgesia and Side Effects"
  • "An Active Controlled Evaluation of the Efficacy and Safety of Dual Opioid Treatment With Morphine Plus Oxycodone for Acute Pain Following Total Knee Arthroplasty"

In the recently completed Phase 3 Combination Rule Study, MoxDuo IR demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components.  The Company is currently completing its final Phase 3 registration trial for MoxDuo IR in patients who have undergone total knee replacement surgery.

When compared to other opioids at equi-analgesic doses, MoxDuo IR reduced the occurrence rate and intensity of moderate to severe nausea, vomiting and dizziness by 50-75% or more (study 021) and demonstrated when such Adverse Events (AEs) do occur they are frequently of shorter duration among MoxDuo IR subjects than the controls.

According to a report published in 2006 in The British Journal of Pharmacology(1), the search for an analgesic that combines opioid-like efficacy without the well known adverse event profile associated with these drugs has been likened to that for the "Holy Grail" of pain therapy.  The rate of occurrence for nausea, vomiting, dizziness, sedation, and constipation, are estimated to occur in "tens of millions" of Americans suffering from acute and chronic pain every year(2).  Incremental costs to the health care system for GI events caused by opioids alone are estimated to range from $4,880 to $36,152 per patient(3).

Therefore, the ability of MoxDuo IR to markedly reduce the occurrence of moderate-severe AEs has important clinical and economic benefits.  Having demonstrated reductions of 50%-75% of adverse events, MoxDuo IR opens the therapeutic window for acute pain patients suffering from moderate to severe pain and provides the potential for significant healthcare cost reductions in the treatment of patients receiving opioid therapy.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.  The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.  QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain.  Data collected from these studies provided additional guidance for optimizing the design and initiation of two pivotal Phase 3 studies required for New Drug Application (NDA) filings with the US Food and Drug Administration (FDA).  QRxPharma expects to complete its Phase 3 program Q4 2010 and file its NDA for MoxDuo®IR by Q1 2011.  The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics.  For more information, visit www.qrxpharma.com.

About IASP

The International Association for the Study of Pain (IASP) is the leading professional forum for science, practice, and education in the field of pain.   The biennial World Congress on Pain meeting, is the world's largest pain-related gathering, and is international and multidisciplinary in scope.

(1)75 years of opioid research: the exciting but vain quest for the Holy Grail – Alistair D. Corbett, Graeme Henderson, Alexander T. McKnight and Stewart J. Paterson: British Journal of Pharmacology (2006) 147, S153-162.

(2)Gregorian Jr., RS et al.  J Pain (May 2010); (EPub ahead of Print): 1-14

(3)Kwong JW, et al.  Ann Pharmacotherapy (2010); 44:630-640


'/>"/>
SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... 2017 , ... In addition to sticking with the new ... approach and use natural alternatives for all house cleaning products, disinfectants, respiratory relief, ... that, the new line of essential oils, are all 100% organic and natural. ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center ... announced today the election of Yie-Hsin Hung to the Board of Directors. , ... Board of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... and highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge ... survival rates. , Preora has been named a Top 100 Finalist ...
(Date:9/21/2017)... New York (PRWEB) , ... September 21, 2017 , ... ... named “One Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda Kuo ... renowned yoga mat art pieces, such as Zen Kodo mat. Wanderlust , one ...
Breaking Medicine News(10 mins):